Fixed-Dose Combination Acetaminophen/Ibuprofen for Postoperative Dental Pain

PainRelief.com Interview with:

Prof Chris Frampton PhD Department of Medicine University of Otago Christchurch, New Zealand

Prof. Frampton

Prof Chris Frampton PhD
Department of Medicine
University of Otago
Christchurch, New Zealand

PainRelief.com: What is the background for this study?

Response: Acute pain is a significant burden to the individual and to society. In light of the ongoing opioid crisis, there is a need for effective nonopioid pain medications that provide improved analgesia over common analgesics, without compromising tolerability. Multimodal analgesia combines multiple drugs with different mechanisms of action to improve pain relief while limiting side effects. Fixed-dose combination tablets containing acetaminophen and ibuprofen are already available in many countries; however, the therapeutic advantages of such products are not available to patients in the United States. The US Food and Drug Administration (FDA) has restricted the dose of acetaminophen in prescription drugs to 325 mg per tablet, therefore an existing product containing acetaminophen 500 mg + ibuprofen 150 mg per tablet (two tablets per dose) has been downscaled to comply with FDA restrictions (acetaminophen 325 mg + ibuprofen 97.5 mg, three tablets per dose). The goal of this study was to determine the efficacy of the new fixed-dose combination of acetaminophen 975 mg and ibuprofen 292.5 mg (FDC 975/292.5) relative to acetaminophen or ibuprofen monotherapy, or placebo following the surgical removal of at least two impacted third molars.

Continue reading

Performance Health and Drew Brees Launch “Safer Pain Relief”

“To help inform Americans about existing, non-prescription solutions for pain relief, Performance Health, makers of Biofreeze Pain Reliever and TheraBand exercise and recovery tools, will partern with NFL pro and current New Orleans Saints quarterback, Drew Brees to launch a national “Safer Pain Relief” campaign.

The “Safer Pain Relief” initiative will address the dangers of misusing opioid pain relievers and the opportunity, in many cases, to use alternatives.

http://www.prweb.com/releases/2017/07/prweb14503305.htm